The DOI matches its Crossref record.
Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies
Open accessAbstract
Objective Significant amyloid deposition is present in approximately half of all cases of dementia with Lewy bodies (DLB). We sought to determine whether amyloid deposition was associated with more rapid clinical decline over 1 year. Methods Twenty-eight participants had a baseline clinical assessment and amyloid PET scan, followed by a further clinical assessment after 1 year. Changes in clinical measures were compared with amyloid deposition assessed by visual rating and cortical standardized uptake value ratio. Results Amyloid deposition on visual rating was associated with greater decline in Mini-Mental State Examination and daily function over 1 year. There was no correlation between cortical standardized uptake value ratio and clinical measures. Conclusions This study provides further evidence for a link between amyloid deposition and clinical progression in DLB. Pathologies such as amyloid, and their interaction with α-synuclein, remain possible treatment targets in DLB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aβ pathology is present in approximately 50% of DLB patients.
“Αβ pathology is present in ~50% of DLB patients and the use of amyloid PET cannot be used for the differential diagnosis of AD and DLB, that are two of the most common types of dementia [174].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [174]
Amyloid PET cannot be used for differential diagnosis of AD and DLB.
“Αβ pathology is present in ~50% of DLB patients and the use of amyloid PET cannot be used for the differential diagnosis of AD and DLB, that are two of the most common types of dementia [174].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [174]
Amyloid PET has been associated with cortical thinning in the hippocampus and greater grey matter loss in the cingulate gyrus and temporal lobe in DLB.
“Amyloid PET has however been associated with cortical thinning in the hippocampus and greater grey matter loss in the cingulate gyrus and temporal lobe in DLB and this may be suggestive of faster neurodegeneration and worse clinical progression in positive Aβ LBD compared to negative status [46, 174, 176].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [174]
Amyloid PET positivity in LBD may be suggestive of faster neurodegeneration and worse clinical progression compared to negative status.
“Amyloid PET has however been associated with cortical thinning in the hippocampus and greater grey matter loss in the cingulate gyrus and temporal lobe in DLB and this may be suggestive of faster neurodegeneration and worse clinical progression in positive Aβ LBD compared to negative status [46, 174, 176].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [174]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- Ossenkoppele, 2015, Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis, JAMA, 313, 1939, 10.1001/jama.2015.4669 · DOI · Paper page
- Donaghy, 2018, Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies, Mov Disord, 33, 1130, 10.1002/mds.27403 · DOI · Paper page
- Mak, 2019, Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies, Neurobiol Aging, 73, 74, 10.1016/j.neurobiolaging.2018.09.004 · DOI · Paper page
- McKeith, 2005, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, 1863, 10.1212/01.wnl.0000187889.17253.b1 · DOI · Paper page
- McKeith, 2017, Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium, Neurology, 89, 88, 10.1212/WNL.0000000000004058 · DOI · Paper page
- Abdelnour, 2016, Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in Lewy body dementia, Mov Disord, 31, 1203, 10.1002/mds.26668 · DOI
- Sarro, 2016, Amyloid-beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies, Brain, 139, 2740, 10.1093/brain/aww193 · DOI · Paper page
- Pletnikova, 2005, Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases, Neurobiol Aging, 26, 1183, 10.1016/j.neurobiolaging.2004.10.006 · DOI
- Clinton, 2010, Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline, J Neurosci, 30, 7281, 10.1523/JNEUROSCI.0490-10.2010 · DOI · Paper page
Cited by
Sorted by citations
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“Αβ pathology is present in ~50% of DLB patients and the use of amyloid PET cannot be used for the differential diagnosis of AD and DLB, that are two of the most common types of dementia [174].”
BackgroundResultSelf-citation
Metadata
- Authors
- Donaghy, P. C., Firbank, M. J., Thomas, A. J., Lloyd, J., Petrides, G., Barnett, N., Olsen, K., & O'Brien, J. T.
- Affiliations
- Newcastle University (GB)
- National Health Service (GB)
- University of Cambridge (GB)
- Corresponding author
- Donaghy, Paul C.
- ORCID
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 28
- Issue
- 5
- Pages
- 573-577
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2997974303
- Cited by
- 31
- References
- 0
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 7 · 2023: 7 · 2022: 3 · 2021: 1 · 2020: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Avid Radiopharmaceuticals
- National Institute for Health Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- dementia with Lewy bodies, amyloid deposition, amyloid PET, clinical progression, cognitive decline, functional decline, standardized uptake value ratio, alpha-synuclein, treatment goals
- MeSH terms
- Mental Status and Dementia Tests, Aged, Aged, 80 and over, Brain, England, Female, Humans, Magnetic Resonance Imaging, Male, Amyloid beta-Peptides, Lewy Body Disease, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
